Traders should monitor FDA review timelines and potential upcoming catalysts, such as priority review designation or PDUFA date announcements. This NDA submission increases the near-term value inflection potential for NUVL stock.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 7 $102.25entry
- T+1 · 7mo ago +2.73%α +0.19% · $105.04
- T+5 · 7mo ago +2.71%α −2.62% · $105.02
- T+20 · 7mo ago +0.36%α −9.42% · $102.62
- T+60 · 5mo ago +21.01%α +7.74% · $123.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nuvalent, Inc. announced the submission of its New Drug Application (NDA) to the U.S. FDA for neladalkib, a treatment for tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer. This is a key regulatory milestone in the company's oncology pipeline.
Key Facts
- Nuvalent submitted a New Drug Application (NDA) to the FDA for neladalkib.
- The drug candidate targets advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors.
- The announcement represents a significant advancement in the company's clinical development program.
- No financial figures or timelines for FDA decision were disclosed in the filing.
Financial Impact
Potential future revenue from neladalkib if approved; no specific figures disclosed.
Risk Factors
- FDA may not approve neladalkib or may require additional data.
- Competition from existing and emerging ALK inhibitors could impact market adoption.
- As a clinical-stage biotech, Nuvalent remains subject to high regulatory and development risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001861560-26-000003 |
| Document: 0001861560-26-000003-index-headers.html | 0001861560-26-000003 |
| Document: 0001861560-26-000003-index.html | 0001861560-26-000003 |
| Document: 0001861560-26-000003.txt | 0001861560-26-000003 |
Track record
18 reports on NUVL
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +3.27% at T+20 after the Mar 30, 2026 report. 3 of 7 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers